MX2009012030A - Formas farmacéuticas sólidas compuestas de un recubrimiento enterico con liberación acelerada del medicamento. - Google Patents
Formas farmacéuticas sólidas compuestas de un recubrimiento enterico con liberación acelerada del medicamento.Info
- Publication number
- MX2009012030A MX2009012030A MX2009012030A MX2009012030A MX2009012030A MX 2009012030 A MX2009012030 A MX 2009012030A MX 2009012030 A MX2009012030 A MX 2009012030A MX 2009012030 A MX2009012030 A MX 2009012030A MX 2009012030 A MX2009012030 A MX 2009012030A
- Authority
- MX
- Mexico
- Prior art keywords
- solid dosage
- enteric coating
- dosage forms
- drug release
- accelerated drug
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invención trata de una forma farmacéutica solida que comprende un recubrimiento interior localizado en entre un núcleo que contiene un ingrediente activo farmacéuticamente activo y u recubrimiento entérico exterior en donde el recubrimiento interior está compuesto de material polimérico anionico neutralizado, y por lo menos un acido carboxílico que tiene 2 a 16 átomos de carbono las sales de los mismos o mezclas de dicho acido y su sal; en donde el recubrimiento exterior está compuesto de un material polimérico anionico que esta menos o no neutralizado en absoluto que el material de recubrimiento interior.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/EP2007/054398 WO2008135090A1 (en) | 2007-05-07 | 2007-05-07 | Solid dosage forms comprising an enteric coating with accelerated drug release |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2009012030A true MX2009012030A (es) | 2010-01-25 |
Family
ID=39410284
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2009012030A MX2009012030A (es) | 2007-05-07 | 2007-05-07 | Formas farmacéuticas sólidas compuestas de un recubrimiento enterico con liberación acelerada del medicamento. |
Country Status (19)
Country | Link |
---|---|
US (2) | US9597293B2 (es) |
EP (1) | EP2152250B1 (es) |
JP (1) | JP5167345B2 (es) |
KR (1) | KR101443943B1 (es) |
CN (1) | CN101663027B (es) |
AU (1) | AU2007352872B2 (es) |
BR (1) | BRPI0721654B8 (es) |
CA (1) | CA2687130C (es) |
CY (1) | CY1122582T1 (es) |
DK (1) | DK2152250T3 (es) |
ES (1) | ES2759626T3 (es) |
HU (1) | HUE046488T2 (es) |
IL (1) | IL201557A (es) |
LT (1) | LT2152250T (es) |
MX (1) | MX2009012030A (es) |
PL (1) | PL2152250T3 (es) |
PT (1) | PT2152250T (es) |
SI (1) | SI2152250T1 (es) |
WO (1) | WO2008135090A1 (es) |
Families Citing this family (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7759506B2 (en) | 2002-02-25 | 2010-07-20 | Diffusion Pharmaceuticals Llc | Bipolar trans carotenoid salts and their uses |
UA95903C2 (ru) | 2005-02-24 | 2011-09-26 | Дифьюжен Фармасьютикалз Ллк | Транс-каротиноиды, их синтез, лекарственная форма и применение |
JP2010524855A (ja) | 2007-04-13 | 2010-07-22 | ディフュージョン・ファーマシューティカルズ・エルエルシー | 末梢血管疾患の前処置としての、及びその処置における双極性トランスカロテノイドの使用 |
SI2230932T1 (sl) | 2008-01-10 | 2017-07-31 | Evonik Roehm Gmbh | Oplaščeni farmacevtski ali nutracevtski pripravek s povečanim sproščanjem aktivne učinkovine v črevesu |
AR070863A1 (es) | 2008-03-11 | 2010-05-12 | Takeda Pharmaceutical | Preparacion solida de desintegracion oral y metodo para suprimir la ruptura de los granulos finos durante la produccion de un comprimido |
AU2010263245A1 (en) | 2009-06-22 | 2012-01-19 | Diffusion Pharmaceuticals Llc | Diffusion enhancing compounds and their use alone or with thrombolytics |
AU2011262361A1 (en) * | 2010-06-02 | 2013-01-10 | Diffusion Pharmaceuticals Llc | Oral formulations of bipolar trans carotenoids |
AU2012305915B2 (en) | 2011-09-07 | 2017-09-07 | Roland Saur-Brosch | Formulation for the controlled release of one or several substances in the digestive tract of a mammal |
RU2014125430A (ru) | 2011-11-24 | 2015-12-27 | Синтон Бв | Контролируемое высвобождение частиц, содержащих диметилфумарат |
JP5917964B2 (ja) * | 2012-03-19 | 2016-05-18 | 富士ゼロックス株式会社 | 錠剤、錠剤の製造方法、錠剤管理装置、錠剤照合装置及びプログラム |
EP2659881B1 (en) * | 2012-04-30 | 2017-11-29 | Tillotts Pharma Ag | A delayed release drug formulation |
CU24343B1 (es) * | 2012-04-30 | 2018-05-08 | Tillotts Pharma Ag | Formulación de fármaco de liberación retardada |
US20130295170A1 (en) * | 2012-05-03 | 2013-11-07 | Kydes Pharmaceuticals Llc | Compositions for control of drug abuse |
KR101973235B1 (ko) | 2012-08-27 | 2019-08-16 | 에보니크 룀 게엠베하 | 에탄올의 영향에 대해 지속 방출 특성 및 내성을 갖는 제약 또는 기능식품 조성물 |
US20140127299A1 (en) * | 2012-11-07 | 2014-05-08 | NaZura BioHealth, Inc. | GRAS Enteric Coating Formulations and Methods of Making and Using Same |
US8859005B2 (en) | 2012-12-03 | 2014-10-14 | Intercontinental Great Brands Llc | Enteric delivery of functional ingredients suitable for hot comestible applications |
TWI688411B (zh) * | 2013-02-22 | 2020-03-21 | 日商志瑞亞新藥工業股份有限公司 | 腸溶錠 |
JP5934835B2 (ja) * | 2013-03-08 | 2016-06-15 | 富士フイルム株式会社 | 腸溶性細粒及び医薬組成物 |
MA38847B2 (fr) * | 2013-10-29 | 2021-02-26 | Tillotts Pharma Ag | Formulation médicamenteuse à libération retardée |
US9744221B2 (en) | 2014-12-23 | 2017-08-29 | Synthetic Biologics, Inc. | Method and compositions for inhibiting or preventing adverse effects of oral antibiotics |
US11780848B2 (en) | 2015-10-16 | 2023-10-10 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1- carboxamide and solid state forms thereof |
US10550126B2 (en) | 2015-10-16 | 2020-02-04 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
US20170129902A1 (en) | 2015-10-16 | 2017-05-11 | Abbvie Inc. | PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-alpha]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF |
US11365198B2 (en) | 2015-10-16 | 2022-06-21 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
US11524964B2 (en) | 2015-10-16 | 2022-12-13 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
US11512092B2 (en) | 2015-10-16 | 2022-11-29 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
KR102489034B1 (ko) | 2016-03-24 | 2023-01-13 | 디퓨젼 파마슈티컬즈 엘엘씨 | 암을 치료하기 위한, 화학 요법 및 방사선 요법과의 양극성 트랜스 카로티노이드의 용도 |
EP3257501A1 (en) | 2016-06-14 | 2017-12-20 | Tillotts Pharma AG | Multiple unit dosage form comprising a core with individual core units covered by a mucoadhesive material, and an enteric core coating |
US11564922B2 (en) | 2017-03-09 | 2023-01-31 | Abbvie Inc. | Methods of treating crohn's disease and ulcerative colitis |
TW201840318A (zh) | 2017-03-09 | 2018-11-16 | 美商艾伯維有限公司 | 治療克羅恩氏病和潰瘍性結腸炎之方法 |
US10524489B2 (en) * | 2017-07-12 | 2020-01-07 | Zinpro Corporation | Method and composition to control rumen release of cobalt to rumen bacteria for making vitamin B12 |
AU2018313766A1 (en) | 2017-08-07 | 2020-02-20 | Finch Therapeutics, Inc. | Compositions and methods for maintaining and restoring a healthy gut barrier |
EP3737750B1 (en) | 2018-01-09 | 2024-06-05 | Theriva Biologics, Inc. | Alkaline phosphatase agents for treatment of neurodevelopmental disorders |
CN112203669A (zh) | 2018-02-23 | 2021-01-08 | 克雷斯顿沃控股公司 | 微生物组相关的免疫疗法 |
CA3094174A1 (en) | 2018-03-20 | 2019-09-26 | Synthetic Biologics, Inc. | Alkaline phosphatase agents for treatment of radiation disorders |
KR20200143724A (ko) * | 2018-04-12 | 2020-12-24 | 비피에스아이 홀딩스, 엘엘씨. | 산성화 코팅 및 코팅된 분해 저항성 기질 |
EP3662895A1 (en) | 2018-12-07 | 2020-06-10 | Tillotts Pharma AG | A process for manufacturing reducing sugar-free 5-asa tablet cores |
EP3662900A1 (en) | 2018-12-07 | 2020-06-10 | Tillotts Pharma AG | Colonic drug delivery formulation |
WO2020114616A1 (en) | 2018-12-07 | 2020-06-11 | Tillotts Pharma Ag | Topical treatment of immune checkpoint inhibitor induced diarrhoea, colitis or enterocolitis using antibodies and fragments thereof |
EP3662902A1 (en) | 2018-12-07 | 2020-06-10 | Tillotts Pharma AG | Colonic drug delivery formulation |
EP3662901A1 (en) | 2018-12-07 | 2020-06-10 | Tillotts Pharma AG | Delayed release drug formulation comprising an outerlayer with an enzymaticyaaly degradable polymer, its composition and its method of manufacturing |
EP3662898A1 (en) | 2018-12-07 | 2020-06-10 | Tillotts Pharma AG | Solid composition comprising mesalazine |
MX2021013527A (es) | 2019-05-15 | 2021-12-10 | Evonik Operations Gmbh | Proceso para preparar capsulas rellenas, de cubierta dura, con recubrimientos basados en copolimero de (met)acrilato con una maquina para llenar capsulas. |
WO2021035665A1 (en) * | 2019-08-30 | 2021-03-04 | Dow Global Technologies Llc | Polar polyolefin dispersion based seed coating composition |
CA3154308A1 (en) | 2019-09-13 | 2021-03-18 | Mark Smith | Compositions and methods for treating autism spectrum disorder |
US20240131082A1 (en) | 2019-10-18 | 2024-04-25 | Finch Therapeutics Holdings Llc | Compositions and Methods for Delivering a Bacterial Metabolite to a Subject |
WO2021097288A1 (en) | 2019-11-15 | 2021-05-20 | Finch Therapeutics Holdings Llc | Compositions and methods for treating neurodegenerative diseases |
CA3160876A1 (en) | 2019-12-11 | 2021-06-17 | Evonik Operations Gmbh | Dosage form comprising an alkaline agent and an enteric coating layer |
IL293648A (en) | 2019-12-11 | 2022-08-01 | Evonik Operations Gmbh | Dosage form for use in the treatment or prevention of disease |
WO2021115649A1 (en) | 2019-12-11 | 2021-06-17 | Evonik Operations Gmbh | Dosage form for use in treating or preventing of a disease |
WO2021142347A1 (en) | 2020-01-10 | 2021-07-15 | Finch Therapeutics Holdings Llc | Compositions and methods for non-alcoholic steatohepatitis (nash) |
WO2021142358A1 (en) | 2020-01-10 | 2021-07-15 | Finch Therapeutics Holdings Llc | Compositions and methods for treating hepatic encephalopathy (he) |
TW202140049A (zh) | 2020-01-10 | 2021-11-01 | 美商芬奇治療控股有限責任公司 | 用於治療b型肝炎(hbv)及d型肝炎(hdv)之組合物及方法 |
WO2021202806A1 (en) | 2020-03-31 | 2021-10-07 | Finch Therapeutics Holdings Llc | Compositions comprising non-viable fecal microbiota and methods of use thereof |
WO2022178294A1 (en) | 2021-02-19 | 2022-08-25 | Finch Therapeutics Holdings Llc | Compositions and methods for providing secondary bile acids to a subject |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS58135807A (ja) | 1982-02-05 | 1983-08-12 | Shin Etsu Chem Co Ltd | 腸溶性被覆薬剤の製造方法 |
DE3208791A1 (de) * | 1982-03-11 | 1983-09-22 | Röhm GmbH, 6100 Darmstadt | Verfahren zum ueberziehen von arzneiformen mittes eines in wasser dispergierten ueberzugsmittels |
GB2189698A (en) * | 1986-04-30 | 1987-11-04 | Haessle Ab | Coated omeprazole tablets |
IT1246382B (it) | 1990-04-17 | 1994-11-18 | Eurand Int | Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon |
US5188836A (en) * | 1990-07-27 | 1993-02-23 | Warner-Lambert Company | Sustained release formulations |
US5580578A (en) * | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
SE9500478D0 (sv) * | 1995-02-09 | 1995-02-09 | Astra Ab | New pharmaceutical formulation and process |
SE9600071D0 (sv) * | 1996-01-08 | 1996-01-08 | Astra Ab | New oral formulation of two active ingredients I |
DE19626045C2 (de) | 1996-06-28 | 1998-12-03 | Klinge Co Chem Pharm Fab | Stabile Arzneiform zur oralen Verabreichung, welche Omeprazol als aktiven Wirkstoff enthält, sowie Verfahren zur Herstellung derselben |
US6623759B2 (en) * | 1996-06-28 | 2003-09-23 | Astrazeneca Ab | Stable drug form for oral administration with benzimidazole derivatives as active ingredient and process for the preparation thereof |
US6312728B1 (en) | 1998-07-07 | 2001-11-06 | Cascade Development, Inc. | Sustained release pharmaceutical preparation |
CA2359812C (en) * | 2000-11-20 | 2004-02-10 | The Procter & Gamble Company | Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures |
MXPA02009478A (es) * | 2001-01-31 | 2003-03-10 | Roehm Gmbh | Forma medicinal de multiples particulas que comrpende por lo menos dos formas de bolitas recubiertas de diferente manera. |
HUP0400264A2 (hu) * | 2001-06-22 | 2004-08-30 | Pfizer Products Inc. | Alacsony oldékonyságú és/vagy savra érzékeny hatóanyagokat és semlegesített savas polimereket tartalmazó gyógyszerkészítmények és eljárás az előállításukra |
CA2444814C (en) * | 2001-10-24 | 2009-06-09 | The Procter & Gamble Company | Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures |
MXPA04004747A (es) | 2001-11-23 | 2004-08-02 | Procter & Gamble | Forma de dosificacion farmaceutica con multiples recubrimientos. |
KR20050008644A (ko) * | 2001-12-21 | 2005-01-21 | 엘지 바이오메디컬 인스티튜트 | 위암에서의 유전자 발현 프로파일 |
DE10208335A1 (de) * | 2002-02-27 | 2003-09-04 | Roehm Gmbh | Arzneiform und Verfahren zu ihrer Herstellung |
JP2005538105A (ja) * | 2002-07-25 | 2005-12-15 | ファルマシア・コーポレーション | 水不溶性ポリマーおよび水溶性の小孔形成物質からなる2層により被覆された固体剤形の製造方法 |
US20040028737A1 (en) * | 2002-08-12 | 2004-02-12 | Kopran Research Laboratories Limited | Enteric coated stable oral pharmaceutical composition of acid unstable drug and process for preparing the same |
RU2351315C2 (ru) * | 2003-07-24 | 2009-04-10 | Смитклайн Бичам Корпорейшн | Пленки, растворяющиеся в полости рта |
RU2382637C2 (ru) | 2004-04-30 | 2010-02-27 | Астеллас Фарма Инк. | Фармацевтическая композиция для перорального введения в форме частиц с рассчитанным временем высвобождения и быстро распадающиеся таблетки, содержащие указанную композицию |
US20090110727A1 (en) * | 2004-10-12 | 2009-04-30 | Eisai R & D Management Co., Ltd. | Extended release compositions of proton pump inhibitors |
DE102005007059A1 (de) | 2005-02-15 | 2006-08-24 | Röhm GmbH & Co. KG | Teilneutralisiertes anionisches (Meth)acrylat-Copolymer |
US9149439B2 (en) * | 2005-03-21 | 2015-10-06 | Sandoz Ag | Multi-particulate, modified-release composition |
DE102005032806A1 (de) * | 2005-07-12 | 2007-01-18 | Röhm Gmbh | Verwendung eines teilneutralisierten, anionischen (Meth)acrylat-Copolymers als Überzug für die Herstellung einer Arzneiform mit einer Wirkstofffreisetzung bei erniedrigten pH-Werten |
DE102006035549A1 (de) | 2006-07-27 | 2008-01-31 | Evonik Röhm Gmbh | Arzneiform mit mindestens zweischichtiger Trennschicht |
CA2661561C (en) | 2006-08-18 | 2013-12-24 | Evonik Roehm Gmbh | Pharmaceutical composition with controlled active ingredient delivery for active ingredients with good solubility in water |
SI2230932T1 (sl) * | 2008-01-10 | 2017-07-31 | Evonik Roehm Gmbh | Oplaščeni farmacevtski ali nutracevtski pripravek s povečanim sproščanjem aktivne učinkovine v črevesu |
-
2007
- 2007-05-07 SI SI200732140T patent/SI2152250T1/sl unknown
- 2007-05-07 WO PCT/EP2007/054398 patent/WO2008135090A1/en active Application Filing
- 2007-05-07 US US12/598,138 patent/US9597293B2/en active Active
- 2007-05-07 PL PL07728851T patent/PL2152250T3/pl unknown
- 2007-05-07 PT PT77288512T patent/PT2152250T/pt unknown
- 2007-05-07 BR BRPI0721654A patent/BRPI0721654B8/pt active IP Right Grant
- 2007-05-07 LT LTEP07728851.2T patent/LT2152250T/lt unknown
- 2007-05-07 CA CA2687130A patent/CA2687130C/en active Active
- 2007-05-07 DK DK07728851T patent/DK2152250T3/da active
- 2007-05-07 KR KR1020097023249A patent/KR101443943B1/ko active IP Right Grant
- 2007-05-07 AU AU2007352872A patent/AU2007352872B2/en active Active
- 2007-05-07 EP EP07728851.2A patent/EP2152250B1/en active Active
- 2007-05-07 JP JP2010506808A patent/JP5167345B2/ja active Active
- 2007-05-07 MX MX2009012030A patent/MX2009012030A/es active IP Right Grant
- 2007-05-07 ES ES07728851T patent/ES2759626T3/es active Active
- 2007-05-07 HU HUE07728851A patent/HUE046488T2/hu unknown
- 2007-05-07 CN CN2007800528650A patent/CN101663027B/zh active Active
-
2009
- 2009-10-15 IL IL201557A patent/IL201557A/en active IP Right Grant
-
2012
- 2012-09-05 US US13/603,984 patent/US10537530B2/en active Active
-
2019
- 2019-12-04 CY CY20191101282T patent/CY1122582T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
AU2007352872A1 (en) | 2008-11-13 |
US10537530B2 (en) | 2020-01-21 |
SI2152250T1 (sl) | 2020-06-30 |
EP2152250A1 (en) | 2010-02-17 |
DK2152250T3 (da) | 2019-12-09 |
LT2152250T (lt) | 2019-12-27 |
BRPI0721654A2 (pt) | 2013-01-29 |
CA2687130A1 (en) | 2008-11-13 |
US20100129446A1 (en) | 2010-05-27 |
BRPI0721654B8 (pt) | 2022-07-05 |
WO2008135090A8 (en) | 2009-03-05 |
US9597293B2 (en) | 2017-03-21 |
HUE046488T2 (hu) | 2020-03-30 |
CN101663027B (zh) | 2013-02-27 |
KR101443943B1 (ko) | 2014-10-07 |
JP5167345B2 (ja) | 2013-03-21 |
IL201557A0 (en) | 2010-05-31 |
AU2007352872B2 (en) | 2013-03-14 |
KR20100016306A (ko) | 2010-02-12 |
CA2687130C (en) | 2017-10-03 |
WO2008135090A1 (en) | 2008-11-13 |
US20130058986A1 (en) | 2013-03-07 |
JP2010526110A (ja) | 2010-07-29 |
IL201557A (en) | 2017-06-29 |
ES2759626T3 (es) | 2020-05-11 |
BRPI0721654B1 (pt) | 2019-10-22 |
PT2152250T (pt) | 2019-12-12 |
PL2152250T3 (pl) | 2020-06-15 |
CN101663027A (zh) | 2010-03-03 |
EP2152250B1 (en) | 2019-09-04 |
CY1122582T1 (el) | 2021-01-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2009012030A (es) | Formas farmacéuticas sólidas compuestas de un recubrimiento enterico con liberación acelerada del medicamento. | |
UA106877C2 (uk) | Фармацевтична композиція ентакапону або його солей пролонгованого вивільнення | |
MX2020011652A (es) | Derivados de piridazina 1,4-disustituida, y su uso para el tratamiento de afecciones relacionadas con la deficiencia de smn. | |
MX2012007375A (es) | 3-ceto-n-propargil 1-aminoindano. | |
MX365522B (es) | Sistemas de administracion y formulacion de farmacos de retencion gastrica, y metodo para su preparacion usando carbonato de calcio funcionalizado. | |
MX2010008138A (es) | Forma de dosis farmaceutica. | |
WO2009058798A3 (en) | Orally disintegrated dosage form | |
BR112015008139A2 (pt) | formulação de forma de dosagem sólida de desintegração rápida compreendendo carbonato de cálcio funcionalizado e método de fabricação dos mesmos | |
UA105229C2 (uk) | Фармацевтичний склад | |
ZA201005615B (en) | Pharmaceutical compositions of entacapone,levodopa and carbidopa with improved bioavailability | |
HK1104791A1 (en) | Dipyridamole extended-release formulations and process for preparing same | |
MX2010007672A (es) | Composicion estabilizada de liberacion sostenida de clorhidrato de bupropion y proceso para su preparacion. | |
PL2205279T3 (pl) | Farmaceutyczna kombinacja aliskirenu i walsartanu | |
MX2010003441A (es) | Formulaciones galenicas de alisquireno y valsartan. | |
MX2012010229A (es) | Forma de dosis de liberacion modificada. | |
PH12021550389A1 (en) | Pharmaceutical composition comprising antiplatelet agent and gastric acid secretion inhibitor | |
NZ591204A (en) | Pharmaceutical compositions and methods for stabilizing the same | |
MX2011007779A (es) | Formulaciones galenicas de compuestos organicos. | |
MY152158A (en) | Solid dosage forms comprising an enteric coating with accelerated drug release | |
WO2008122994A3 (en) | Stable pharmaceutical compositions of clopidogrel bisulfate and process of preparation thereof | |
JO3239B1 (ar) | تركيبات جالينية من مركبات عضوية | |
WO2012064130A3 (ko) | 대장 선택성 셀레콕시브 전구체 화합물 및 이를 유효성분으로 함유하는 대장성 질환 치료 또는 예방용 약학조성물 | |
MY160963A (en) | Sustained-release therapeutic agent for hypertension and renal dysfunction | |
WO2012028922A3 (en) | Controlled release pharmaceutical compositions of milnacipran | |
WO2014119984A3 (es) | Composición farmacéutica con un sistema bifásico de liberación inmediata para el control de eventos convulsivos y del dolor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |